Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

XOMA - XOMA Corp


IEX Last Trade
28.86
0   0%

Share volume: 0
Last Updated: Fri 20 Dec 2024 09:01:15 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.46%

PREVIOUS CLOSE
CHG
CHG%

$28.86
-3.36
0.13%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
11%
Profitability 0%
Dept financing 9%
Liquidity 75%
Performance 5%
Company vs Stock growth
vs
Performance
5 Days
-0.04%
1 Month
-10.17%
3 Months
0.15%
6 Months
5.03%
1 Year
47.45%
2 Year
60.25%
Key data
Stock price
$28.86
P/E Ratio 
-12.19
DAY RANGE
$25.50 - $28.86
EPS 
-$2.17
52 WEEK RANGE
$18.85 - $35.00
52 WEEK CHANGE
$47.45
MARKET CAP 
342.356 M
YIELD 
N/A
SHARES OUTSTANDING 
11.704 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
BETA 
0.68
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$41,912
AVERAGE 30 VOLUME 
$38,210
Company detail
CEO: James R. Neal, EMBA
Region: US
Website: xoma.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets with commercial sales potential.

Recent news